Request Sample
Request Methodology
Description
Merkel Cell Carcinoma Treatment Market size was valued at USD 3.38 billion in 2021, growing at a CAGR of 3.9% from 2022-28. Merkel cell carcinoma is an uncommon type of skin cancer and is also known as neuroendocrine skin carcinoma or trabecular carcinoma. It occurs due to the abnormal growth of Merkel cells. This cancer has grown and spreads rapidly beyond the skin. Merkel cells are the type of skin neuroendocrine cells as they share some features with hormone making and nerve cells. Merkel cells are found at the base of the epidermis, the top layer of the skin and are very close to nerve endings which helps us to sense touch and light. The report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers.
Key Developments:
In 2017 September, Merck KGaA and Pfizer Inc. received market authorization from European Commission for its BAVENCIO (avelumab) for the treatment of metastatic Merkel cell carcinoma.
In March 2017, Merck KGaA and Pfizer Inc. received U.S.FDA approval for its BAVENCIO (avelumab) for the treatment of metastatic Merkel cell carcinoma.
